End Of Phase II Meetings Used By Less Than Half The Firms In PwC Survey
Executive Summary
Fewer than half of drug companies participating in a PricewaterhouseCoopers survey participated in a meeting with FDA at the conclusion of Phase II studies
You may also be interested in...
Flawed Junovan Trial Design Leads Committee To Doubt Efficacy Results
Problems in clinical trial design for IDM Pharma's osteosarcoma drug Junovan (mifamurtide) could have been rectified if the sponsor had held an end-of-Phase II meeting with FDA prior to study initiation, the agency said in briefing documents for a May 9 meeting of the Oncologic Drugs Advisory Committee
“Critical Path” Is On The Road Forward; FDA Reports Industry Activity Is High
The Critical Path Initiative is entering 2007 with growing momentum, bolstered by a new, tailored agency infrastructure and increased industry awareness of FDA's initiative to spur drug development
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals